Physician Race, %(n) |
|
American Indian or Alaska Native |
1% (5) |
Asian |
9% (35) |
African American |
5% (19) |
Pacific Islander |
< 1% (1) |
White |
76% (291) |
Others |
6% (21) |
Physician Hispanic ethnicity, %(n) |
4% (15) |
Physician male gender, %(n) |
74% (283) |
Physician certified addiction training, %(n) |
28% (104) |
Specialty (not mutually exclusive) |
|
Internal Medicine, %(n) |
19% (74) |
Family practice, %(n) |
34% (131) |
HIV/ID, % (n) |
4% (15) |
Addiction medicine, %(n) |
25% (97) |
Psychiatry, %(n) |
32% (123) |
Percent of time on patient treatment, mean (SD) |
81%(22.5) |
Years since graduation, mean (SD) |
24.3 (11.1) |
Years prescribing buprenorphine, %(n) |
|
≤ 3 Years |
72% (273) |
> 3 Years |
28% (106) |
Urban setting, %(n) |
56% (216) |
Addiction setting, %(n) |
22% (83) |
Treated >50 buprenorphine patients, %(n) |
40% (149) |
Percent of patients male, mean (SD) |
61% (25) |
Percent of patients white, mean (SD) |
79% (27) |
Percent of patients Hispanic, mean (SD) |
8% (16) |
Percent of patients age 18–40 years, mean (SD) |
62% (28) |
Percent uninsured, mean (SD) |
18% (27) |
Percent using prescription opioids, mean (SD) |
64% (30) |
Percent using intravenous heroin, mean (SD) |
21% (26) |